Action STABL STAYBLE THERAPEUTICS AB
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Stayble Therapeutics AB

Actions

STABL

SE0013513652

Marché Fermé - Nasdaq Stockholm
Autres places de cotation
 17:20:18 15/05/2024 		Varia. 5j. Varia. 1 janv.
0,2705 SEK +13,89% Graphique intraday de Stayble Therapeutics AB +2,08% -10,73%
20/02 Stayble Therapeutics AB (publ) annonce ses résultats pour le quatrième trimestre et l'exercice clos le 31 décembre 2023 CI
2023 Stayble Therapeutics annonce que de nouvelles analyses de l'étude de phase IIb renforcent le projet de hernie discale CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Stayble's CEO to BioStock: "We are looking forward to new study results in 2024"
BioStock: Stayble's new analyses of phase IIb study strengthen disc herniation project
Stayble Therapeutics Announces New Analyses of Phase IIb Study Strengthen Disc Herniation Project
BioStock: Stayble Therapeutics shifts focus to phase Ib study in disc herniation
Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
BioStock: Stayble did not reach the primary endpoint in phase IIb
BioStock: Stayble Therapeutics presents phase IIb data within one month
Toleranzia Appoints Successor to Outgoing CFO
BioStock: Stayble reports last patient last visit in the phase IIb study
Stayble Therapeutics Terminates Liquidity Provider Agreement
BioStock: Stayble enrols the first patient in herniated disc study
Stayble Enters the First Patient in Herniated Disc Study
Stayable Therapeutics Enrols First Patient for Herniated Discs Trial
BioStock: Progress for Stayble Therapeutics in the second quarter
Stayble Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Certain Shares of Stayble Therapeutics AB are subject to a Lock-Up Agreement Ending on 22-AUG-2023.
BioStock: Stayble's phase IIb study nears the finishing line
Stayble Therapeutics Phase IIb Study Nears the Final Line
BioStock: Stayble Therapeutics looks towards its most important year so far
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action STABL
  4. Actualités Stayble Therapeutics AB
  5. Autres langues